Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Indo-Bangla Pharmaceuticals's Enterprise Value is BDT0.00 Mil.
Indo-Bangla Pharmaceuticals does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Indo-Bangla Pharmaceuticals's EV-to-EBIT at this moment.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Indo-Bangla Pharmaceuticals's Enterprise Value is BDT0.00 Mil.
Indo-Bangla Pharmaceuticals does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Indo-Bangla Pharmaceuticals's EV-to-EBITDA at this moment.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Indo-Bangla Pharmaceuticals's Enterprise Value is BDT0.00 Mil.
Indo-Bangla Pharmaceuticals does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Indo-Bangla Pharmaceuticals's EV-to-Revenue at this moment.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Indo-Bangla Pharmaceuticals (DHA:IBP) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
Indo-Bangla Pharmaceuticals Enterprise Value Related Terms
Indo-Bangla Pharmaceuticals Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo-Bangla Pharmaceuticals Enterprise Value Chart
Indo-Bangla Pharmaceuticals Annual Data
Trend
Enterprise Value
Indo-Bangla Pharmaceuticals Semi-Annual Data
Enterprise Value
DHA:IBP vs : Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Indo-Bangla Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo-Bangla Pharmaceuticals Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indo-Bangla Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Indo-Bangla Pharmaceuticals's Enterprise Value falls into.
Indo-Bangla Pharmaceuticals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo-Bangla Pharmaceuticals (DHA:IBP) has a Enterprise Value of BDT0.00 Mil as of Jun. 27, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Indo-Bangla Pharmaceuticals and its competitors.
Is Indo-Bangla Pharmaceuticals' Enterprise Value too high?
Indo-Bangla Pharmaceuticals' current Enterprise Value is BDT0.00 Mil. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' Enterprise Value compare to ?
Indo-Bangla Pharmaceuticals' Enterprise Value of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Indo-Bangla Pharmaceuticals and its competitors. Indo-Bangla Pharmaceuticals's current Enterprise Value is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current Enterprise Value of BDT0.00 Mil. The current Enterprise Value is BDT0.00 Mil. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current Enterprise Value is BDT0.00 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score
Get the complete analysis for DHA:IBP
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:IBP has been successfully added to your 